Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Debt (2016 - 2025)

Historic Total Debt for Ironwood Pharmaceuticals (IRWD) over the last 14 years, with Q3 2025 value amounting to $584.5 million.

  • Ironwood Pharmaceuticals' Total Debt rose 4612.65% to $584.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $584.5 million, marking a year-over-year increase of 4612.65%. This contributed to the annual value of $385.0 million for FY2024, which is 2293.22% down from last year.
  • Ironwood Pharmaceuticals' Total Debt amounted to $584.5 million in Q3 2025, which was up 4612.65% from $584.3 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Total Debt peaked at $599.1 million during Q2 2023, and registered a low of $112.9 million during Q2 2021.
  • Its 5-year average for Total Debt is $380.5 million, with a median of $412.5 million in 2024.
  • Its Total Debt has fluctuated over the past 5 years, first tumbled by 2905.82% in 2024, then soared by 4612.65% in 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Total Debt (Quarter) stood at $116.9 million in 2021, then grew by 3.19% to $120.6 million in 2022, then surged by 314.29% to $499.6 million in 2023, then dropped by 22.93% to $385.0 million in 2024, then surged by 51.82% to $584.5 million in 2025.
  • Its last three reported values are $584.5 million in Q3 2025, $584.3 million for Q2 2025, and $385.0 million during Q1 2025.